Phenocell and amarna therapeutics awarded eurostars grant to assess a gene therapy for dry amd using a novel 3-dimensional ipsc-derived retinal model of the disease

Grasse, france and leiden, the netherlands – 11 december 2024 – phenocell sas (part of axol bioscience) a leading provider of stem cell-derived models and services, and amarna therapeutics, a biotechnology pioneer in innovative gene therapies, are pleased to announce that their joint project amd-halt has been awarded with a prestigious eurostars grant. this funding by eurostars will support their collaboration to validate amarna's patented gene therapy platform using a novel and advanced cellular disease model for dry age-related macular degeneration (dry amd), one of the leading causes of vision loss worldwide.
AMD Ratings Summary
AMD Quant Ranking